New Publication: Blood-Based Detection of Aβ Oligomers Reveals Impaired Clearance in Alzheimer’s Disease
We are proud to share that our latest study featuring attyloid’s sFIDA technology has been published in Nature Communications Medicine. Using highly sensitive sFIDA assays, we successfully quantified amyloid-beta (Aβ) oligomers in plasma samples from the prestigious DELCODE cohort.
Our key findings revealed a surprising reduction in Aβ oligomer levels in Alzheimer’s disease (AD) and subjective cognitive decline (SCD) patients compared to healthy controls—challenging earlier reports that suggested increased levels. Importantly, the study uncovered a correlation between plasma and cerebrospinal fluid (CSF) oligomer concentrations, linking impaired Aβ clearance to the ApoE ε4 risk factor.
These results provide novel insights into Alzheimer’s disease pathophysiology and highlight the potential of blood-based Aβ oligomers as biomarkers for early diagnosis and drug development.
We thank Prof. Oliver Peters and the DELCODE team at DZNE for their outstanding collaboration in making this study possible.